Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-20-013093)

Filing Details

Accession Number:: 0000899243-20-013093
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-14 16:41:08
Reporting Period:: 2020-05-12

Accepted Time:: 2020-05-14 16:41:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1797336	Ayala Pharmaceuticals Inc.	AYLA	()	E9

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1652458	Israel Biotech Fund I, L.p.	75 Fort Street Clifton House, Po Box 1350 Grand Cayman E9 KY1-1108		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-05-12	369,231	$0.00	2,878,362	No	4	C	Direct
Common Stock	Acquisiton	2020-05-12	211,757	$0.00	3,090,119	No	4	C	Direct
Common Stock	Acquisiton	2020-05-12	225,000	$15.00	3,315,119	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-05-12	738,462	$0.00	369,231	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-05-12	423,514	$0.00	211,757	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of preferred stock was automatically converted into 0.5 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.